Zelluna ASA Logo

Zelluna ASA

Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.

ULTI | OL

Overview

Corporate Details

ISIN(s):
NO0010851603
LEI:
254900B4VALJZR9TL744
Country:
Norway
Address:
Ullernchausseen 64, 0379 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Zelluna ASA is a clinical-stage biopharmaceutical company focused on developing treatments for solid cancers. The company is pioneering a proprietary, allogeneic T-cell receptor-based Natural Killer (TCR-NK) cell therapy platform. This "off-the-shelf" approach merges the targeting capabilities of T-cell receptors with the therapeutic functions of NK cells to address significant unmet medical needs in oncology. Zelluna's mission is to deliver transformative, safe, and cost-efficient therapies with the potential to cure patients with advanced solid tumors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 07:50
Board/Management Information
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financia…
English 4.2 KB
2025-11-27 08:35
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 1.8 KB
2025-11-25 16:05
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 1.4 KB
2025-11-25 12:09
Major Shareholding Notification
ZELLUNA ASA: DISCLOSURE OF LARGE SHAREHOLDING
English 1.5 KB
2025-11-25 11:32
Post-Annual General Meeting Information
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
English 325.0 KB
2025-11-25 11:32
Post-Annual General Meeting Information
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025 - Attachm…
Norwegian 258.2 KB
2025-11-25 11:32
Post-Annual General Meeting Information
Zelluna ASA - Extraordinary General Meeting held on November 25, 2025
English 1.5 KB
2025-11-04 13:04
Pre-Annual General Meeting Information
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025 - Atta…
Norwegian 1014.6 KB
2025-11-04 13:04
Pre-Annual General Meeting Information
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025
English 1.4 KB
2025-11-04 09:10
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 986 bytes
2025-11-04 08:28
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 1.2 KB
2025-11-04 07:29
Major Shareholding Notification
Zelluna ASA: Disclosure of large shareholding
English 2.1 KB
2025-11-04 07:00
Share Issue/Capital Change
Zelluna ASA - Ex. date
English 550 bytes
2025-11-04 00:58
Share Issue/Capital Change
Zelluna ASA - Key information relating to subsequent offering
English 2.8 KB
2025-11-04 00:35
Share Issue/Capital Change
Zelluna ASA - Mandatory notification of trade - Attachment: 20251104 - PDMR att…
English 219.0 KB

Automate Your Workflow. Get a real-time feed of all Zelluna ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Zelluna ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Zelluna ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden
ODI
Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea
226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America
OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France
ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France
ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway
OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan
4588
ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America
ONCY
Onconetix, Inc. Logo
Develops diagnostics and therapeutics for men's health and oncology markets.
United States of America
ONCO

Talk to a Data Expert

Have a question? We'll get back to you promptly.